drugset / Trial / NCT00116571

Photodynamic Therapy (PDT) for Lower Urinary Tract Symptoms (PLUS)

NCT00116571 ↗

Phase 2 Terminated 180 enrolled QLT Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine if transurethral photodynamic therapy with lemuteporfin has a therapeutic effect on lower urinary tract symptoms due to an enlarged prostate. Photodynamic therapy (known as "PDT") is a treatment that uses light to make a drug work. This means the drug is "light-activated". Light-activated drugs do not work until a certain color of light shines on the drug. When the drug and the light combine, they react together to destroy tissue. This study is investigating PDT with lemuteporfin as a possible treatment for an enlarged prostate. PDT with lemuteporfin may destroy overgrown prostate tissue and help urinary symptoms go back to normal.

Timeline

Start
2005-05
Primary completion
—
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Lemuteporfin Small molecule — Other